Evidence map›Paper›PMID 34944630›Full record

ArticleBiomedicines2021

Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells.

Sonam Kumari, Mohammed Sikander, Shabnam Malik, Manish K Tripathi, Bilal B Hafeez, Murali M Yallapu, Subhash C Chauhan, Sheema Khan, Meena Jaggi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sonam KumariDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Mohammed SikanderDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Shabnam MalikDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Manish K TripathiDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Bilal B HafeezDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Murali M YallapuDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0002-0073-8828
Subhash C ChauhanDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Sheema KhanDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Meena JaggiDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
University of Tennessee Health Science Center · US

Funding

MUC13 Mucin in Colorectal Cancer Health DisparityR01CA204552 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2020
$1.7M
Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Targeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
NIH HHS R01 CA204552NIH HHS R01 CA206069NIH HHS R01 CA210192
6 · The paper itself

Abstract

Pancreatic cancer has the worst prognosis and lowest survival rate among all cancers. Pancreatic cancer cells are highly metabolically active and typically reprogrammed for aberrant glucose metabolism; thus they respond poorly to therapeutic modalities. It is highly imperative to understand mechanisms that are responsible for high glucose metabolism and identify natural/synthetic agents that can repress glucose metabolic machinery in pancreatic cancer cells, to improve the therapeutic outcomes/management of pancreatic cancer patients. We have identified a glycoside, steviol that effectively represses glucose consumption in pancreatic cancer cells

Indexed as

glucose metabolismpancreatic cancerstevioltranslation initiation

Identifiers

PMID34944630
PMCPMC8698284
OpenAlexW3217649106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.